[207 Pages Report] Sales in the global Radiation-Induced Myelosuppression Treatment Market are slated to total US$ 2.9 Billion in 2022. Expanding at a steady 3.1% CAGR, the market valuation is projected to top US$ 3.5 Billion in 2028.
| Attribute | Details |
|---|---|
| Radiation-Induced Myelosuppression Treatment Estimated Market Size 2022 | US$ 2.9 Billion |
| Radiation-Induced Myelosuppression Treatment Market Value-based CAGR (2022 to 2028) | 3.1% |
| Radiation-Induced Myelosuppression Treatment Market Projected Size in 2028 | US$ 3.5 Billion |
Increasing incidence of cancer worldwide is underpinning the need for advanced cancer treatment options and therapies. Early diagnosis and the availability of radiotherapy and chemotherapy are expected to fuel sales in the market through 2031.
In addition to this, the introduction of adjuvant therapy for cancer is playing a vital role in reducing the death rate of cancer, improving disease management, and the overall quality of life in cancer patients. As per Future Market Insights, the market is projected to expand on the back of the aforementioned factors over the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 3.42% |
| H1, 2022 Projected | 3.12% |
| H1, 2022 Outlook | 2.62% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 50 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 80 ↓ |
Future Market Insights presents a comparative analysis about the market growth rates and development prospects in the global market. According to FMI analysis, the radiation-induced myelosuppression treatment market is expected to drop by 80 Basis Point Share (BPS) in H1- 2022 compared to H1-2021.
However, BPS change of only 50 BPS was observed when comparing H1-2022 Outlook and H1-2022 Projected growth. Key reason for this dip in BPS is attributed to the factor such as stringent government regulations and approval process for pipeline products, which impacted the growth of the market.
However, some positive factors which will influence the market growth in future include new developments and introduction of novel therapeutics for treatment of radiation induced myelosuppression. For instance, on Feb 2021, FDA approved trilaciclib (Cosela, G1 Therapeutics) for lowering the rate of chemotherapy-induced myelosuppression (CIM) in adult patients suffering from extensive-stage small-cell lung cancer (ES-SCLC).
Demand in the radiation-induced myelosuppression treatment market is projected to increase at a 3.1% CAGR, in comparison to the 3.4% CAGR registered between 2013 to 2031.
The availability of various growth factors and favorable treatment guidelines have made the management of neutropenia easier. However, thrombocytopenia and anemia are still posing a burden on the healthcare system.
Thrombocytopenia can be managed with the help of available growth factors, but most of them are off-label. The management of anemia remains a challenge for cancer patients who receive radiation therapy for cancer treatment.
Due to changes in reimbursement and labeling of medications for anemia, the use of off-label indication erythropoietin-stimulating agents has decreased to an extent. This has resulted in growing need for blood transfusion, which is associated with various risk factors.
This, in turn, is underscoring the significance of myelosuppression treatment therapeutics and drugs, which is expected to boost the market over the assessment period.
Principal Consultant
Anemia is a common consequence of chronic kidney diseases (CKD) and radiation-induced myelosuppression. Due to the insufficiency of erythropoietin synthesis, patients suffer from anemia. However, the combination of erythropoiesis-stimulating agents (ESA) and iron has become a standard treatment for anemia.
ESAs effectively increase the hemoglobin (Hb) levels in patients. However, their use has been associated with increased cardiovascular risk, especially due to high dose intake in inflamed and hyporesponsive patients.
Iron deficiency is another consequence of anemia. This has resulted in the introduction of intravenous iron therapy which is beneficial for anemic patients, CKD patients, and patients dealing with heart failure.
A new class of drugs, namely prolyl hydroxylase domain (PHD) inhibitors is now available for the treatment of anemia. These drugs effectively stimulate the synthesis of endogenous erythropoietin and increase iron availability.
In addition to this, in February, the U.S. Food and Drug Administration (FDA) approved Cosela (Trilaciclib) as the first line of treatment in its class to reduce the frequency of bone marrow suppression in adults, which is caused by chemotherapy for the extensive stage.
Such developments are expected to provide impetus to the growth of the market over the assessment period, opines FMI.
“High Prevalence of Chemotherapy Induced Myelosuppression Will Spur Demand in the U.S.”
The U.S. is expected to dominate the North America radiation-induced myelosuppression treatment market owing to growing incidence of cancer, chronic kidney diseases (CKD), and patients dealing with heart failure.
The presence of leading market players and fast-tracked approvals by the FDA are expected to augment the growth of the U.S. market. In addition to this, the U.S. is home to a vast healthcare sector, which is expected to provide opportunities for growth to market players over the assessment period.
“Healthcare Providers are Prescribing Myelosuppressive Chemotherapy Drugs To improve Bone Marrow Function”
China is expected to account for a lion’s share of the East Asia radiation-induced myelosuppression treatment market. Increasing geriatric population in the country, along with high incidence of cancer and heart failure are spurring the demand for myelosuppression treatment drugs.
Further, increasing research and development activities for the development of iron deficiency treatment is expected to augment the growth of the market. Iron deficiency is a consequence of anemia caused by chemotherapy radiation.
Growing preference for erythropoiesis-stimulating agents (ESAs) for iron deficiency in the country is anticipated to boost the market in the forthcoming years.
“Surging Trend of Medical Tourism Will Boost Sales of Myelosuppression Chemotherapy Drugs”
The U.K. is expected to emerge as a lucrative pocket in the Europe radiation-induced myelosuppression treatment market owing to the influx of medical tourists in the country, along with the availability of superior healthcare facilities.
Increasing adoption of technologically advanced medical equipment for the treatment of various chronic disorders such and cancer and kidney failure in the country is expected to augment the growth of the market in the forthcoming years.
Further, rising awareness regarding adjuvant treatment for cancer in the U.K. will continue boosting the market over the assessment period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“Surging Incidence of Neutropenia to Drive Preference for Myelosuppression Treatment Regimen”
Based on indication, sales in the neutropenia segment are projected to account for 43.3% of the total market share in 2022. Neutropenia is a condition where an individual deals with abnormally low counts of white blood cells.
Bone marrow malfunction caused by chemotherapy radiations is a chief factor driving sales in this segment. Lack of white blood cells in patients weakens the immune system and their ability to fight infections, which makes it imperative to seek treatment for the same.
Owing to the aforementioned factors, sales in this segment are projected to increase at a considerable pace over the assessment period.
“Rising Awareness Regarding New Erythropoietin Stimulating Agents Will Bolster Sales”
In terms of drug class, demand in the erythropoietin stimulating agents (ESA) segment is projected to remain high over the assessment period. ESAs effectively improve the efficacy of iron therapy in anemic patients after chemotherapy radiations, which is expected to continue pushing sales in the market.
Besides this, growing preference for intravenous iron therapy with a combination of ESAs is expected to complement the growth of the market in the forthcoming years. The combination of ESAs and IV iron therapy improve the red blood cells count as compared to other treatment using ESAs alone.
“Sales of Myelosuppression Chemotherapy Drugs to Remain High Via Hospital Pharmacies”
Based on the sales channel, sales in the hospital pharmacies segment are projected to increase at a considerable pace owing to the wide availability of therapeutic drugs in these shops. However, high convenience and timely delivery offered by online pharmacies will place them as a lucrative segment over the assessment period.
“Oral Route of Administration for Myelosuppression Chemotherapy Medication to Gain Traction”
In terms of route of administration, the oral route is expected to be preferred by both healthcare professionals and patients owing to ease of administration and high efficacy. Growing preference for non-invasive treatment options will also provide impetus to sales in this segment.
Leading players operating in the global radiation-induced myelosuppression treatment market are investing in research and development to improve lines of treatment for myelosuppression treatment. In addition to this, players are investing in mergers and acquisitions to strengthen their distribution channels.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Units for Volume and US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania, and MEA |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, others. |
| Key Market Segments Covered | Indication, Drug Class, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Amgen Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd; Mylan N.V.; Pfizer Inc.; Janssen Global Services, LLC (Johnson & Johnson); Partner Therapeutics, Inc.; Mission Pharmacal Company; Myelo Therapeutics GmbH; Pluristem Therapeutics Inc. |
| Pricing | Available upon Request |
Indication:
Drug Class:
Route of Administration:
Distribution Channel:
Region
The global radiation-induced myelosuppression treatment market is expected to reach a valuation of US$ 2.9 Bn in 2022.
The global Radiation-induced myelosuppression treatment market grew at a 3.4% CAGR between 2013 and 2021.
Increasing preference for non-invasive drug administration, along with the introduction of intravenous iron therapy are key trends driving radiation-induced myelosuppression treatment sales.
North America is projected to account for a dominant share of the global radiation-induced myelosuppression treatment market share during the forecast period.
The radiation-induced myelosuppression treatment market in Europe is anticipated to expand at a considerable pace over the assessment period.
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
2.3. Inclusion and Exclusions
3. Radiation Induced Myelosuppression Treatment Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Radiation Induced Myelosuppression Treatment Market Evolution
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
5. Macroeconomic Assumptions
6. Global Economic Outlook
6.1. Gross Domestic Product by Region & Country, 2016 – 2021
7. Key Inclusions
7.1. Key Regulations
7.2. Pipeline Assessment
7.3. Patient Treatment Regimen/Patient Journey
8. Global Market Analysis 2013–2021 and Forecast 2022–2028
8.1. Market Value Share Analysis
8.2. Y-o-Y Growth Analysis
8.3. Absolute $ Opportunity
9. North America Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013–2021
9.2.1. U.S.
9.2.2. Canada
9.3. Market Size (US$ Mn) Forecast By Country, 2022–2028
9.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021
9.4.1. Growth Factors
9.4.1.1. Granulocyte Colony-Stimulating Factor
9.4.1.2. Thrombopoietin Receptor Agonists
9.4.2. Erythropoietin-stimulating Agents
9.4.3. Thrombopoietic Agents
9.4.4. Iron supplementation
9.4.5. Others
9.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028
9.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021
9.6.1. Oral
9.6.2. Injectable
9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028
9.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021
9.8.1. Anemia
9.8.2. Neutropenia
9.8.3. Thrombocytopenia
9.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028
9.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
9.10.1. Hospital Pharmacies
9.10.2. Retail Pharmacies
9.10.3. Drug Stores
9.10.4. Online Pharmacies
9.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Drug Class
9.12.3. By Route of Administration
9.12.4. By Indication
9.12.5. By Distribution Channel
9.13. Drivers and Restraints – Impact Analysis
10. Latin America Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) By Country, 2013–2021
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Argentina
10.2.4. Rest of Latin America
10.3. Market Size (US$ Mn) Forecast By Country, 2022–2028
10.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021
10.4.1. Growth Factors
10.4.1.1. Granulocyte Colony-Stimulating Factor
10.4.1.2. Thrombopoietin Receptor Agonists
10.4.2. Erythropoietin-stimulating Agents
10.4.3. Thrombopoietic Agents
10.4.4. Iron supplementation
10.4.5. Others
10.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028
10.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021
10.6.1. Oral
10.6.2. Injectable
10.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028
10.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021
10.8.1. Anemia
10.8.2. Neutropenia
10.8.3. Thrombocytopenia
10.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028
10.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Drug Stores
10.10.4. Online Pharmacies
10.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028
10.12. Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Drug Class
10.12.3. By Route of Administration
10.12.4. By Indication
10.12.5. By Distribution Channel
10.13. Drivers and Restraints – Impact Analysis
11. Western Europe Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) By Country, 2013–2021
11.2.1. Germany
11.2.2. France
11.2.3. U.K.
11.2.4. Spain
11.2.5. Italy
11.2.6. Rest of Western Europe
11.3. Market Size (US$ Mn) Forecast By Country, 2022–2028
11.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021
11.4.1. Growth Factors
11.4.1.1. Granulocyte Colony-Stimulating Factor
11.4.1.2. Thrombopoietin Receptor Agonists
11.4.2. Erythropoietin-stimulating Agents
11.4.3. Thrombopoietic Agents
11.4.4. Iron supplementation
11.4.5. Others
11.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028
11.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021
11.6.1. Oral
11.6.2. Injectable
11.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028
11.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021
11.8.1. Anemia
11.8.2. Neutropenia
11.8.3. Thrombocytopenia
11.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028
11.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Drug Stores
11.10.4. Online Pharmacies
11.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Drug Class
11.12.3. By Route of Administration
11.12.4. By Indication
11.12.5. By Distribution Channel
11.13. Drivers and Restraints – Impact Analysis
12. Eastern Europe Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028
12.1. Introduction
12.2. Historical Market Size (US$ Mn) By Country, 2013–2021
12.2.1. Russia
12.2.2. Poland
12.2.3. Rest of Eastern Europe
12.3. Market Size (US$ Mn) Forecast By Country, 2022–2028
12.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021
12.4.1. Growth Factors
12.4.1.1. Granulocyte Colony-Stimulating Factor
12.4.1.2. Thrombopoietin Receptor Agonists
12.4.2. Erythropoietin-stimulating Agents
12.4.3. Thrombopoietic Agents
12.4.4. Iron supplementation
12.4.5. Others
12.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028
12.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021
12.6.1. Oral
12.6.2. Injectable
12.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028
12.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021
12.8.1. Anemia
12.8.2. Neutropenia
12.8.3. Thrombocytopenia
12.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028
12.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Drug Stores
12.10.4. Online Pharmacies
12.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028
12.12. Market Attractiveness Analysis
12.12.1. By Country
12.12.2. By Drug Class
12.12.3. By Route of Administration
12.12.4. By Indication
12.12.5. By Distribution Channel
12.13. Drivers and Restraints – Impact Analysis
13. Asia Pacific excluding China (APEC) Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028
13.1. Introduction
13.2. Historical Market Size (US$ Mn) By Country, 2013–2021
13.2.1. China
13.2.2. India
13.2.3. Australia and New Zealand
13.2.4. ASEAN
13.2.5. Rest of APAC
13.3. Market Size (US$ Mn) Forecast By Country, 2022–2028
13.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021
13.4.1. Growth Factors
13.4.1.1. Granulocyte Colony-Stimulating Factor
13.4.1.2. Thrombopoietin Receptor Agonists
13.4.2. Erythropoietin-stimulating Agents
13.4.3. Thrombopoietic Agents
13.4.4. Iron supplementation
13.4.5. Others
13.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028
13.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021
13.6.1. Oral
13.6.2. Injectable
13.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028
13.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021
13.8.1. Anemia
13.8.2. Neutropenia
13.8.3. Thrombocytopenia
13.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028
13.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Drug Stores
13.10.4. Online Pharmacies
13.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028
13.12. Market Attractiveness Analysis
13.12.1. By Country
13.12.2. By Drug Class
13.12.3. By Route of Administration
13.12.4. By Indication
13.12.5. By Distribution Channel
13.13. Drivers and Restraints – Impact Analysis
14. Japan Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021
14.2.1. Growth Factors
14.2.1.1. Granulocyte Colony-Stimulating Factor
14.2.1.2. Thrombopoietin Receptor Agonists
14.2.2. Erythropoietin-stimulating Agents
14.2.3. Thrombopoietic Agents
14.2.4. Iron supplementation
14.2.5. Others
14.3. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028
14.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021
14.4.1. Oral
14.4.2. Injectable
14.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028
14.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021
14.6.1. Anemia
14.6.2. Neutropenia
14.6.3. Thrombocytopenia
14.7. Market Size (US$ Mn) Forecast By Indication, 2022–2028
14.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Drug Stores
14.8.4. Online Pharmacies
14.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028
14.10. Market Attractiveness Analysis
14.10.1. By Drug Class
14.10.2. By Route of Administration
14.10.3. By Indication
14.10.4. By Distribution Channel
14.11. Drivers and Restraints – Impact Analysis
15. MEA Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028
15.1. Introduction
15.2. Historical Market Size (US$ Mn) By Country, 2013–2021
15.2.1. GCC Countries
15.2.2. South Africa
15.2.3. Rest of MEA
15.3. Market Size (US$ Mn) Forecast By Country, 2022–2028
15.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021
15.4.1. Growth Factors
15.4.1.1. Granulocyte Colony-Stimulating Factor
15.4.1.2. Thrombopoietin Receptor Agonists
15.4.2. Erythropoietin-stimulating Agents
15.4.3. Thrombopoietic Agents
15.4.4. Iron supplementation
15.4.5. Others
15.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028
15.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021
15.6.1. Oral
15.6.2. Injectable
15.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028
15.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021
15.8.1. Anemia
15.8.2. Neutropenia
15.8.3. Thrombocytopenia
15.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028
15.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
15.10.1. Hospital Pharmacies
15.10.2. Retail Pharmacies
15.10.3. Drug Stores
15.10.4. Online Pharmacies
15.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028
15.12. Market Attractiveness Analysis
15.12.1. By Country
15.12.2. By Drug Class
15.12.3. By Route of Administration
15.12.4. By Indication
15.12.5. By Distribution Channel
15.13. Drivers and Restraints – Impact Analysis
16. Forecast Factors: Relevance and Impact
17. Forecast Assumptions
18. Competition Analysis
18.1. Competition Dashboard
18.2. Market Structure Analysis
18.3. Company Deep Dive
18.3.1. Amgen Inc.
18.3.1.1. Overview
18.3.1.2. Product and Application Portfolio
18.3.1.3. Production Footprint
18.3.1.4. Sales Footprint
18.3.1.5. Channel Footprint
18.3.1.6. Strategy
18.3.1.6.1. Marketing Strategy
18.3.1.6.2. Product Strategy
18.3.1.6.3. Channel Strategy
18.3.2. Novartis AG
18.3.3. Teva Pharmaceutical Industries Ltd
18.3.4. Mylan N.V.
18.3.5. Pfizer Inc.
18.3.6. Janssen Global Services, LLC (Johnson & Johnson)
18.3.7. Partner Therapeutics, Inc.
18.3.8. Mission Pharmacal Company
18.3.9. Myelo Therapeutics GmbH
18.3.10. Pluristem Therapeutics Inc.
19. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Region
19.1. Introduction / Key Findings
19.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013–2021
19.2.1. North America
19.2.2. Latin America
19.2.3. Western Europe
19.2.4. Eastern Europe
19.2.5. Asia Pacific excluding Japan
19.2.6. Japan
19.2.7. Middle East and Africa
19.3. Market Size (US$ Mn) Forecast By Region, 2022–2028
19.4. Market Attractiveness Analysis By Region
20. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021
20.2.1. Growth Factors
20.2.1.1. Granulocyte Colony-Stimulating Factor
20.2.1.2. Thrombopoietin Receptor Agonists
20.2.2. Erythropoietin-stimulating Agents
20.2.3. Thrombopoietic Agents
20.2.4. Iron supplementation
20.2.5. Others
20.3. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028
20.4. Market Attractiveness Analysis By Drug Class
21. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration
21.1. Introduction
21.2. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021
21.2.1. Oral
21.2.2. Injectable
21.3. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028
21.4. Market Attractiveness Analysis By Route of Administration
22. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Indication
22.1. Introduction
22.2. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021
22.2.1. Anemia
22.2.2. Neutropenia
22.2.3. Thrombocytopenia
22.3. Market Size (US$ Mn) Forecast By Indication, 2022–2028
22.4. Market Attractiveness Analysis By Indication
23. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
23.1. Introduction
23.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021
23.2.1. Hospital Pharmacies
23.2.2. Retail Pharmacies
23.2.3. Drug Stores
23.2.4. Online Pharmacies
23.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028
23.4. Market Attractiveness Analysis By Distribution Channel
24. Research Methodology
Explore Healthcare Insights
View Reports
Radiation-Induced Myelosuppression Treatment Market
